Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents.

Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Abstract Text:

I Youlyouz-Marfak,N Gachard,C Le Clorennec,I Najjar,F Baran-Marszak,L Reminieras,E May,G W Bornkamm,R Fagard,J Feuillard,I Youlyouz-Marfak,N Gachard,C Le Clorennec,I Najjar,F Baran-Marszak,L Reminieras,E May,G W Bornkamm,R Fagard,J Feuillard,

Chemotherapeutic drugs such as fludarabine(*), doxorubicin or cisplatin are very potent activators of the anti-oncogene p53. Convergent studies suggest that p53 and STAT1 (signal transducer and activator of transcription 1) cooperate in the induction of cell death. We show that these drugs are also activators of STAT1 in p53-expressing cells, but not in p53-null cells. STAT1 activation was obtained in the presence of both the secretion inhibitor brefeldine A and the inhibitor of RNA synthesis, actinomycin D. p53-dependent STAT1 activation was reversed by overexpression of MDM2 and siRNAs against p53. Genetic analysis of p53 showed that expression of transcriptionally inactive p53 punctual mutants markedly increased Y701-STAT1 phosphorylation, and suggests that the p53 DNA-binding domain was alternatively involved in STAT1 activation or p53 multimerization. Immunoprecipitation experiments showed that ataxia telangiectasia mutated, p53, STAT1 and c-Abl1 (Abelson murine leukaemia viral oncogene homologue 1) were associated together. Treatment of cells with the c-Abl1 tyrosine kinase inhibitor STI571 decreased STAT1 activation by genotoxic drugs. Finally, genotoxic agents sensitized cells in response to very low doses of both interferon alpha and gamma (IFNalpha and gamma). These results show that genotoxic drugs induce STAT1 activation, an effect that depends on p53 protein but not on p53 transcriptional activity, and point to a novel pathway of STAT1 activation by genotoxic drugs, with involvement of c-Abl1 tyrosine kinase in sensitizing cells to IFN response.Cell Death and Differentiation (2008) 15, 376-385; doi:10.1038/sj.cdd.4402270; published online 9 November 2007.

Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Publishing Authors By Initials

I Youlyouz-Marfak,N Gachard,C Le Clorennec,I Najjar,F Baran-Marszak,L Reminieras,E May,GW Bornkamm,R Fagard,J Feuillard,I Youlyouz-Marfak,N Gachard,C Le Clorennec,I Najjar,F Baran-Marszak,L Reminieras,E May,GW Bornkamm,R Fagard,J Feuillard,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cell death and differentiation

VOLUME: 15

Page Numbers: 376-85

Journal Abbreviation: Cell Death Differ.

ISSN: 1350-9047

DAY: 9

MONTH: 11

YEAR: 2007

Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9437445

Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents.

AFFILIATION: 1Centre National de la Recherche Scientifique, UMR CNRS 6101, Faculté de Médecine de Limoges, Université de Limoges, CHU Dupuytren, Laboratoire d'Hématologie, Limoges, France, Equipe labellisée de la Ligue Nationale Contre le Cancer.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cell Death Differ

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents Related Publications

• "6 markers/5 colors" extended white blood cell differential by flow cytometry.
• Full Tensorial characterization of PZN-12%PT single crystal by resonant ultrasound spectroscopy.
• Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents.
• Modeling of a high frequency ultrasonic transducer using periodic structures.
• Splenic marginal zone lymphomas and lymphoplasmacytic lymphomas originate from B-cell compartments with two different antigen-exposure histories.